Healthcare Cost and Utilization for Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis
Alex Hoover1, Paige Reimche2, Dave Watson2, Lynn Tanner2, Laura Gilchrist2,3, Mike Finch2, Yoav H Messinger2, Lucie M. Turcotte1
Affiliations: 1. Optum Labs Visiting Fellow, University of Minnesota Medical School, Minneapolis, MN; 2. Children’s Minnesota, Minneapolis, MN. 3. St. Catherine University, St. Paul, MN.
Funding: This work was supported in part by the NIH-NRSA Research Fellowship in Translational & Genomic Pediatric Cancer Epidemiology - T32CA099936 (AH), the National Cancer Institute Grant No. K08CA234232 (LMT); the Pine Tree Apple Classic Fund (LG, YHM); and the Children’s Cancer Research Fund (LMT).
Corresponding author: Alex Hoover, MD, Division of Pediatric Blood and Marrow Transplantation, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN 55455; email: hoove231@umn.edu
Abstract word count: 245 words
Main text word count: 1993 words
2 tables, 2 figures included
Keywords: cost, CAR-T, pediatric, ALL
Running head: Cost of CAR-T Therapy in Pediatric ALL
Abbreviations Table